Research analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a report issued on Wednesday. The brokerage set a “sell” rating on the stock.
Oragenics Price Performance
NYSE:OGEN opened at $1.09 on Wednesday. The business’s fifty day moving average is $1.88. The firm has a market capitalization of $4.88 million, a PE ratio of -0.12 and a beta of 0.31. Oragenics has a fifty-two week low of $1.02 and a fifty-two week high of $7.74.
Oragenics (NYSE:OGEN – Get Free Report) last released its earnings results on Friday, March 29th. The company reported ($5.48) earnings per share (EPS) for the quarter.
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Articles
- Five stocks we like better than Oragenics
- Financial Services Stocks Investing
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Do ETFs Pay Dividends? What You Need to Know
- Lockheed Martin Stock Aims for a Fresh All-Time High
- NYSE Stocks Give Investors a Variety of Quality Options
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
